Free shipping on all orders over $ 500

Avasimibe

Cat. No. M1814

All AbMole products are for research use only, cannot be used for human consumption.

Avasimibe Structure
Synonym:

CI-1011, PD 148515

Size Price Availability Quantity
5mg USD 30  USD30 In stock
10mg USD 50  USD50 In stock
25mg USD 82  USD82 In stock
50mg USD 160  USD160 In stock
100mg USD 290  USD290 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Avasimibe (CI-1011) is a novel orally bioavailable ACAT inhibitor with IC50 values of 2.9, 13.9, 26.5 µM for CYP2C9, CYP1A2 and CYP2C19, respectively. Avasimibe inhibited ACAT-1 expression and cholesterol ester synthesis in glioma cell lines. Moreover, Avasimibe inhibited the growth of the cells by inducing cell cycle arrest and induced apoptosis as a result of caspase-8 and caspase-3 activation. Avasimibe induced cholesterol 7alpha-hydroxylase and increased bile acid synthesis in cultured rat hepatocytes, and its administration to rats did not produce an increase in lithogenicity index of the bile. The hypolipidemic efficacy of the compound was demonstrated in cholesterol-fed as well as in non-cholesterol-fed animals. In these models, plasma cholesterol levels were reduced, mainly due to the decrease in the non-HDL cholesterol fraction. Clinical data are scarce, but in a study performed in 130 men and women with combined hyperlipidemia and hypoalphalipoproteinemia, avasimibe, 50-500 mg/day, significantly reduced plasma total triglyceride and VLDL-cholesterol. Although total cholesterol, LDL-cholesterol, and HDL-cholesterol were unchanged, it must be stressed that animal data suggest that avasimibe may have direct antiatherosclerotic activity in addition to its cholesterol-lowering effect. Avasimibe treatment can also contribute to increase plaque stability, as it reduces the accumulation of lipids in the arterial wall, inhibits macrophage infiltration into the media and reduces matrix metalloproteinase expression and activity.

Chemical Information
Molecular Weight 501.72
Formula C29H43NO4S
CAS Number 166518-60-1
Solubility (25°C) DMSO ≥90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Yunshu Gao, et al. Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting FoxM1-AKR1C1 Signaling

[2] Yidan Luo, et al. Avasimibe inhibits the proliferation, migration and invasion of glioma cells by suppressing linc00339

[3] Jin-Yi Liu, et al. Avasimibe exerts anticancer effects on human glioblastoma cells via inducing cell apoptosis and cell cycle arrest

[4] Ying Jiang, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma

[5] No authors listed. Drugs R D. Avasimibe. CI 1011

Related Cytochrome P450 (e.g. CYP17) Products
Musk ketone

Musk ketone is a widely used artificial fragrance. Musk ketone is also a cytochrome P450 enzyme inducer. Musk ketone shows mutagenic and comutagenic effects in Hep G2 cells and induces neural stem cell proliferation and differentiation in cerebral ischemia via activation of the PI3K/Akt signaling pathway.

MS-PPOH 

MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor.

(R)-Mephenytoin

(R)-Mephenytoin ((-)-Mephenytoin), the R-enantiomer of Mephenytoin.

(3S,5S)-Atorvastatin

(3S,5S)-Atorvastatin is a inactive enantiomer of Atorvastatin.

(3S,5S)-Atorvastatin sodium salt

(3S,5S)-Atorvastatin sodium salt is a pregnane X receptor (PXR) activator and the inactive enantiomer of Atorvastatin.

  Catalog
Abmole Inhibitor Catalog




Keywords: Avasimibe, CI-1011, PD 148515 supplier, Cytochrome P450 (e.g. CYP17), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.